Wall Street analysts expect that Recro Pharma Inc (NASDAQ:REPH) will announce $13.32 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Recro Pharma’s earnings, with estimates ranging from $13.30 million to $13.35 million. Recro Pharma posted sales of $17.36 million during the same quarter last year, which suggests a negative year-over-year growth rate of 23.3%. The firm is expected to report its next quarterly earnings results on Monday, March 5th.
According to Zacks, analysts expect that Recro Pharma will report full year sales of $13.32 million for the current fiscal year, with estimates ranging from $62.50 million to $66.14 million. For the next fiscal year, analysts expect that the business will report sales of $66.09 million per share, with estimates ranging from $63.60 million to $70.93 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that that provide coverage for Recro Pharma.
Recro Pharma (NASDAQ:REPH) last posted its earnings results on Thursday, November 9th. The specialty pharmaceutical company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.27. Recro Pharma had a negative net margin of 51.88% and a negative return on equity of 60.01%.
Several analysts recently weighed in on REPH shares. Zacks Investment Research cut shares of Recro Pharma from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. Piper Jaffray Companies reissued a “buy” rating and issued a $11.00 price objective on shares of Recro Pharma in a research note on Friday, October 27th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $11.65.
Recro Pharma (REPH) traded up $0.04 during midday trading on Thursday, hitting $8.93. 163,894 shares of the company’s stock were exchanged, compared to its average volume of 87,771. The company has a current ratio of 1.59, a quick ratio of 1.35 and a debt-to-equity ratio of 0.50. Recro Pharma has a 12-month low of $5.81 and a 12-month high of $10.59. The company has a market capitalization of $170.80, a PE ratio of -4.08 and a beta of -0.50.
In other Recro Pharma news, major shareholder Scp Vitalife Partners (Israel) sold 12,964 shares of the company’s stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $8.88, for a total transaction of $115,120.32. Following the sale, the insider now owns 734,269 shares of the company’s stock, valued at $6,520,308.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Scp Vitalife Partners Ii Lp sold 13,189 shares of the company’s stock in a transaction on Wednesday, December 27th. The shares were sold at an average price of $9.56, for a total transaction of $126,086.84. Following the sale, the insider now directly owns 2,243,064 shares in the company, valued at approximately $21,443,691.84. The disclosure for this sale can be found here. In the last three months, insiders sold 860,414 shares of company stock worth $8,289,916. 21.60% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently modified their holdings of REPH. OxFORD Asset Management LLP boosted its position in Recro Pharma by 364.3% during the second quarter. OxFORD Asset Management LLP now owns 203,430 shares of the specialty pharmaceutical company’s stock valued at $1,430,000 after acquiring an additional 159,619 shares during the last quarter. State Street Corp bought a new stake in Recro Pharma during the second quarter valued at $1,047,000. Northern Trust Corp boosted its position in Recro Pharma by 428.5% during the second quarter. Northern Trust Corp now owns 178,437 shares of the specialty pharmaceutical company’s stock valued at $1,254,000 after acquiring an additional 144,676 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Recro Pharma by 787.4% during the second quarter. Dimensional Fund Advisors LP now owns 129,560 shares of the specialty pharmaceutical company’s stock valued at $911,000 after acquiring an additional 114,960 shares during the last quarter. Finally, JT Stratford LLC bought a new stake in Recro Pharma during the second quarter valued at $704,000. 61.55% of the stock is currently owned by institutional investors and hedge funds.
About Recro Pharma
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.